Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models. (October 2020) - Smyth, T.; Brothwood, J.; Fazal, L.; Hearn, K.; Hindley, C.; Johnson, C.; Jones, M.; Kandola, N.; Lyons, J.; Martins, V.; Miyadera, K.; Muench, S.; et al.